WHO says it awaits full clinical data from Merck on antiviral pill molnupiravir

The World Health Organization is awaiting full clinical data on the antiviral pill made by Merck & Co Inc to treat mild-to-moderate COVID-19 patients, a WHO spokesperson said on Tuesday, a day after the company said it had applied for US emergency use authorization.

WHO spokesperson Christian Lindmeier, asked at a UN briefing in Geneva about the drug, said: “Indeed, this is an interesting development. We would have to see the full data about it. If it holds true, then it is another weapon in the fight against the COVID-19 pandemic.”

The treatment, molnupiravir, cut the rate of hospitalization and death by 50 percent in a trial of mild-to-moderately ill patients who had at least one risk factor for the disease, according to data released this month.

Check Also

US intel warns China could dominate advanced technologies

US officials are issuing new warnings about China’s ambitions in artificial intelligence and a range …

Leave a Reply

Your email address will not be published. Required fields are marked *